Dr Matiko Riro

Study Title

Economic studies of using dihydroartemisinin-piperaquine, with and without azithromycin, as an alternative to sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy for the control of malaria and co-infections in pregnancy in Kenya

Research Hypothesis:

We will assess the cost-effectiveness, budget impact and equity impact of using dihydroartemisinin-piperaquine (DP), with and without azithromycin, as an alternative to SP for IPTp for the control of malaria and co-infections in pregnancy

Research Objectives:

To assess the cost-effectiveness of using dihydroartemisinin-piperaquine (DP), with and without azithromycin, as an alternative to SP for IPTp for the control of malaria and co-infections in pregnancy

To assess the budget impact of using dihydroartemisinin-piperaquine (DP), with and without azithromycin, as an alternative to SP for IPTp for the control of malaria and co-infections in pregnancy.

To assess the equity impact of using dihydroartemisinin-piperaquine (DP), with and without azithromycin, as an alternative to SP for IPTp for the control of malaria and co-infections in pregnancy

Profile:

Matiko Riro is a medical doctor who graduated from University of Nairobi in 2009 with a Bachelor’s Degree in Medicine and Surgery (MBChB) and has an MSc in Public Health (Health Economics) from the London School of Hygiene & Tropical Medicine (LSHTM). He is also a Commonwealth Scholar and has previously worked at the Ministry of Health in Kenya and supported a number of health system strengthening projects in sub-Saharan Africa.